AbbVie said its GAAP and adjusted non-GAAP results for Q2 2025 are expected to include acquired IPR&D and milestones expense of $823 million on a pre-tax basis, representing an unfavorable impact of $0.42 to diluted earnings per share.

1. 01

   AbbVie said its GAAP and adjusted non-GAAP results for Q2 2025 are expected to include acquired IPR&D and milestones expense of $823 million on a pre-tax basis, representing an unfavorable impact of $0.42 to diluted earnings per share.

2. 02

   The company said its adjusted diluted earnings per share guidance range for Q2 2025 is $2.84 - $2.88, including the impact of Q2 acquired IPR&D and milestones expense.

3. 03

   AbbVie said its full-year 2025 adjusted diluted earnings per share guidance range, including Q2 acquired IPR&D and milestones expense, is $11.67 - $11.87 (in millions, except per share data). Previously announced guidance excluding this expense was $12.09 - $12.29.

4. 04

   The company presented acquired IPR&D and milestones expense of $1,071 million (in millions) in its annual guidance table, with previously announced guidance of $248 million and Q2 expense of $823 million. It said acquired IPR&D and milestones expense incurred beyond Q2 cannot be reliably forecasted and is excluded.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.